Select Bibliography

Filter by any of these (after searching):

There are 81 items

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint - Trial-Description-Only - GU - AFT-19

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance)

Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series

Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014

Abstract - Primary - Long-Term-Followup - GU - CALGB-9687

Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy

Apolo, Andrea B. , Ostrovnaya, Irina , Halabi, Susan ... - - J. Natl. Cancer Inst - 2013

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90102

External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.

Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90102

Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation

Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019

Abstract - No-Endpoint - Trial-Description-Only - GU - A031501

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009

Manuscript - Primary - Primary - GU - CALGB-99903

Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90203

Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)

Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials

Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017

Manuscript - Primary - Primary - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary - Primary - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary - Primary - GU - A031203

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018

Manuscript - Secondary - Primary - GU - A031203

p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007

Abstract - Primary - Primary - GU - CALGB-159807 , CALGB-9682

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study

D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008

Manuscript - Secondary - Primary - GU - CALGB-9682

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008

Manuscript - Secondary - Primary - GU - CALGB-159807 , CALGB-9682

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008

Manuscript - Primary - Primary - GU - CALGB-90004

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary - Primary - GU - CALGB-90203

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer.

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - AUA - Journal of Urology - 2019

Abstract - Primary - Primary - GU - CALGB-90203

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

Feldman, D , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, MJ ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

George, Daniel J. , Hessel, Colin , Halabi, Susan ... - - Oncologist - 2019

Manuscript - Secondary - Primary - GU - A031203

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480.

George, Daniel J , Halabi, Susan , Shepard, Timothy F , Sanford, Ben ... - - Clin. Cancer Res. - 2005

Manuscript - Primary - Primary - GU - INT-0159

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - GU - A031203

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Halabi, S. , Kelly, W. K. , Kaplan, E. B. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

Halabi, S. , Ou, S. , Vogelzang, N. J. , Scher, H. I. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original - Comprehensive - GU - Comprehensive

Is progression free survival a predictor of overall survival in men with castration recurrent prostate cancer (CRPC)?

Halabi, S. , Ou, S. , Vogelzang, N. J. ... - ASCO GU - - 2008

Abstract - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-90006 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813 , INT-0159

Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Halabi, S. , Rini, B. I. , Stadler, W. M. , Archer, L. E. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)

Halabi, S. , Vogelzang, N. J. , Kornblith, A. B. , Archer, L. E. ... - ASCO GU - Genitourinary Cancers Symposium - 2009

Abstract - Secondary-not-in-original - Primary - GU - C9181 , C9182 , INT-0159

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Halabi, Susan , Kelly, William Kevin , Ma, Hua , Zhou, Haojin ... - - J. Clin. Oncol - 2016

Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-90601

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Meta-Analysis - GU - CALGB-90401 , S9916

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Halabi, Susan , Lin, Chen-Yen , Kelly, W. Kevin , Fizazi, Karim S. ... - - J. Clin. Oncol - 2014

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy

Halabi, Susan , Lin, Chen-Yen , Small, Eric J. , Armstrong, Andrew J. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.

Halabi, Susan , Ou, San-San , Vogelzang, Nicholas J ... - - Cancer - 2007

Manuscript - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-90006 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813

Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Halabi, Susan , Rini, Brian , Escudier, Bernard , Stadler, Walter M. ... - - Cancer - 2014

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90206

Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

Halabi, Susan , Vogelzang, Nicholas J. , Ou, San-San , Owzar, Kouros ... - - J Clin Oncol - 2009

Manuscript - Secondary-not-in-original - Comprehensive - GU - Comprehensive

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Halabi, Susan , Vogelzang, Nicholas J , Kornblith, Alice B ... - - J. Clin. Oncol. - 2008

Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-9840 , C9181 , C9182

The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.

Halabi, Susan , Vogelzang, Nicholas J , Ou, San-San ... - - J. Urol. - 2007

Manuscript - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-9000 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813 , INT-0159

Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy

Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206

Harzstark, A. L. , Halabi, S. , Stadler, W. M. , Vaena, D. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

Hurria, Arti , Cirrincione, Constance T. , Muss, Hyman B. ... - - J Clin Oncol - 2011

Manuscript - Primary - Primary - GU - CALGB-360401 , CALGB-99809

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809

Hurwitz, M. D. , Halabi, S. , Archer, L. , Mcginnis, L. S. ... - - Cancer - 2011

Manuscript - Primary - Primary - GU - CALGB-99809

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008

Manuscript - Primary - Preliminary - GU - CALGB-99809

A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

Jatoi, Aminah , Burch, Patrick , Hillman, David , Vanyo, Joanne M ... - - Urology - 2007

Manuscript - Secondary-not-in-original - Primary - GU - N0351

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study.

Kantoff, P W , Halabi, S , Conaway, M , Picus, J , Kirshner, J ... - - J. Clin. Oncol. - 1999

Manuscript - Primary - Primary - GU - C9182

Five-year follow-up of a multicenter phase II study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen-deprivation therapy (ADT) prior to radiation therapy in patients with unfavorable-risk localized prostate cancer: CALGB 99811

Kelly, W. K. , Halabi, S. , Archer, L. E. , Bogart, J. A. ... - ASCO GU - Genitourinary Cancers Symposium - 2010

Abstract - Primary - Long-Term-Followup - GU - CALGB-99811

Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

Kelly, W. K. , Halabi, S. , Carducci, M. A. , George, D. J. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castrate resistant prostate cancer (metCRPC): Survival results of CALGB 90401

Kelly, W. K. , Halabi, S. , George, D. J. , Stadler, W. M. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Primary - GU - CALGB-90401

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

Kelly, William Kevin , Halabi, Susan , Carducci, Michael ... - - J. Clin. Oncol - 2012

Manuscript - Primary - Primary - GU - CALGB-90401

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.

Kelly, William Kevin , Halabi, Susan , Elfiky, Aymen , Ou, San-San ... - - Cancer - 2008

Manuscript - Primary - Primary - GU - CALGB-99811

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)

Kim, Hyung L. , Halabi, Susan , Li, Ping , Mayhew, Greg , Simko, Jeff ... - - EBioMedicine - 2015

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-150603 , CALGB-90206

A prognostic model for overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance)

Kim, Hyung L. , Halabi, Susan , Li, Ping , Mayhew, Greg , Simko, Jeff ... - AUA - J Urol - 2015

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206

Kluger, Harriet M. , Halabi, Susan , Solomon, Nicole C ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

Mohler, James L. , Halabi, Susan , Ryan, Stephen T. , Al-Daghmin, Ali ... - - Prostate Cancer Prostatic Dis. - 2019

Manuscript - Primary - Primary - GU - CALGB-9687

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782

Monk, J.P. , Halabi, S. , Picus, J. , Hussain, A. , Philips, G. ... - - Cancer - 2012

Manuscript - Primary - Primary - GU - CALGB-9782

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Morris, Michael J. , Heller, Glenn , Bryce, Alan , Armstrong, Andrew ... - ASCO - J Clin Oncol - 2019

Abstract - Primary - Primary - GU - A031201

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

Nixon, A. B. , Halabi, S. , Shterev, I. , Starr, M. D. , Brady, J. C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary - Primary - GU - C90206

Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

Patel, Jai N. , Jiang, Chen , Hertz, Daniel L. , Mulkey, Flora A. ... - - Cancer - 2015

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).

Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Philips, G. K. , Halabi, S. , Sanford, B. L. , Bajorin, D. ... - - Ann Oncol - 2009

Manuscript - Primary - Primary - GU - CALGB-90102

Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782.

Picus, J. , Halabi, S. , Small, E. , Hussain, A. , Philips, G. ... - - J. Clin. Oncol. - 2006

Abstract - Primary - Primary - GU - CALGB-9782

A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006

Picus, Joel , Halabi, Susan , Kelly, W. Kevin ... - - Cancer - 2011

Manuscript - Primary - Primary - GU - CALGB-90006

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Regan, M. M. , O'Donnell, E. K. , Kelly, W. K. , Halabi, S. ... - - Ann Oncol - 2010

Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-99813

CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO GU - Genitourinary Cancers Symposium - 2008

Abstract - Primary - Preliminary - GU - CALGB-90206

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - - J. Clin. Oncol. - 2009

Abstract - Primary - Primary - GU - CALGB-90206

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2010

Manuscript - Primary - Primary - GU - CALGB-90206

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2008

Manuscript - Primary - Preliminary - GU - CALGB-90206

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Rosenberg, J. E. , Halabi, S. , Sanford, B. L. , Himelstein, A. L. ... - - Ann. Oncol - 2008

Manuscript - Primary - Primary - GU - CALGB-90207

CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Rosenberg, Jonathan , Ballman, Karla , Halabi, Susan , Watt, Colleen ... - ASCO - J Clin Oncol - 2019

Abstract - Primary - Primary - GU - CALGB-90601

Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel

Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - - Clin Genitourin Cancer - 2020

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Decline in serumandrogens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: results from CALGB 90401 (Alliance)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K , Russell, Carly ... - EAU - Eur Urol - 2018

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

Ryan, Charles J , Dutta, Sandipan , Kelly, William K , Russell, Carly ... - - Prostate Cancer Prostatic Dis. - 2020

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Ryan, Charles J , Halabi, Susan , Ou, San-San , Vogelzang, Nicholas J ... - - Clin. Cancer Res. - 2007

Manuscript - Secondary-not-in-original - Primary - GU - CALGB-9583

The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).

Small, E. J. , Halabi, S. , Carducci, M. A. , Ryan, C. J. ... - - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Small, Eric J , Halabi, Susan , Dawson, Nancy A , Stadler, Walter M ... - - J. Clin. Oncol. - 2004

Manuscript - Primary - Primary - GU - CALGB-9583

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

Smith, M. R. , Halabi, S. , Ryan, C. J. , Stadler, W. M. , Hussain, A. ... - - J. Clin. Oncol. - 2013

Abstract - Primary - Primary - GU - CALGB-90202

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Smith, Matthew R. , Halabi, Susan , Ryan, Charles J. , Hussain, Arif ... - - J. Clin. Oncol - 2014

Manuscript - Primary - Primary - GU - CALGB-90202

Management of recurrent prostate cancer after radiotherapy: Results from CALGB 9687, a contemporary prospective multi-institutional salvage radical prostatectomy series

Sokoloff, M. H. , Steinberg, G. D. , Halabi, S. , Sanford, B. L. ... - AUA - J Urol - 2008

Abstract - Primary - Primary - GU - CALGB-9687

Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.

Wallace, Kris , Fleshner, Neil , Jewett, Michael , Basiuk, Joan ... - - J. Clin. Oncol. - 2006

Manuscript - Secondary-not-in-original - Primary - GU - Z0070

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO - J Clin Oncol - 2019

Abstract - No-Endpoint - Trial-Description-Only - GU - A031704